SWSusanne Wieschowski

Susanne Wieschowski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susanne Wieschowski has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Strech

    QUEST Center for Responsible Research, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

    9 shared publications
  • Maia Salholz-Hillel

    QUEST Center for Responsible Research, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

    6 shared publications
  • Till Bruckner

    Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; UiT The Arctic University of Norway, Tromsø, Norway; TranspariMED, Stockholm, Sweden

    5 shared publications
  • André Bleich

    Affiliation Institute for Laboratory Animal Science, Hannover Medical School, Hannover, Germany

    3 shared publications
  • Daniel Strech

    QUEST Center for Transforming Biomedical Research, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany

    3 shared publications
  • Delwen Louise Franzen

    QUEST Center for Responsible Research, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany

    3 shared publications

Latest Publications

  • Open Access

    Registration and reporting of clinical trials affiliated with California universities and with primary completion date from 2014 to 2017

    by Mario Malički, Vladislav Nachev, Susanne Wieschowski, Nicole Hildebrand, Stefanie Gestrich, Samruddhi Yerunkar, Emmanuel Zavalis, Benjamin Gregory Carlisle, Delwen L. Franzen, Maia Salholz-Hillel, et al.

    Background: Public information on US clinical trials is shared through the ClinicalTrials.gov registry. This study’s goal was to determine prospective registration, results reporting, trial registration number reporting, and publication accessibility status for trials with primary completion dates from 2014 to 2017 affiliated with seven California universities. Methods: We identified trials with investigators, sponsors, or responsible parties affiliated with seven California universities and searched for their results publications manually. We then used semi-automatic methods to determine prospective registration, summary results reporting in a registry, publication status, and reporting of registration numbers in the abstract and the full text of manuscripts. Results: We identified 1091 unique trials. Most trials were single-center ( n = 752, 69%) and had a median of 50 participants (IQR 21 to 150). Overall, 64% of trials ( n = 698) were prospectively registered, 46% ( n = 500) had summary results reported in the registry, 69% ( n = 750) had results published as articles, and an additional 3% ( n = 36) as abstracts or posters. Results reporting (summary, articles, abstracts or posters) occurred for 58% of trials ( n = 637) within 2 years, and for 81% ( n = 888) within 5 years of the study’s primary completion date. Of journal publications, 77% ( n = 579) were open access publications, 37% ( n = 276) had trial registration numbers listed in their abstract, and 45% ( n = 336) in the manuscript. Only 92 (8%) of these trials were legally required to report results, and only 2 (2%) of those were overdue and under the primary responsibility of a California university to report. Conclusions: Almost one fifth of clinical trials with primary completion dates from 2014 to 2017 with investigators, sponsors or responsible parties affiliated with seven California biomedical research universities lacked any results reporting 5 years after their primary completion, and only 58% reported results within 2 years. Even though a large majority of these trials were completed before US legal mandates for reporting, there was an ethical requirement that the burden to research participants should be commensurate with the scientific value of the research. Research has no public scientific value if its results are not reported.


  • Open Access

    Registration and Reporting of Clinical Trials Affiliated with California Universities and with Primary Completion Date from 2014 to 2017

    by Mario Malički, Vladislav Nachev, Susanne Wieschowski, Nicole Hildebrand, Stefanie Gestrich, Samruddhi Yerunkar, Emmanuel Zavalis, Benjamin Gregory Carlisle, Delwen L. Franzen, Maia Salholz-Hillel, et al.

    Background Public information on US clinical trials is shared through the ClinicalTrials.gov registry. This study’s goal was to determine prospective registration, results reporting, trial registration number reporting, and publication accessibility status for trials with primary completion dates from 2014 to 2017 affiliated with seven California universities. Methods We identified trials with investigators, sponsors, or responsible parties affiliated with seven California universities and searched for their results publications manually. We then used semi-automatic methods to determine prospective registration, summary results reporting in a registry, publication status, and reporting of registration numbers in the abstract and the full text of manuscripts. Results We identified 1,091 unique trials. Most trials were single-center (n=752, 69%) and had a median of 50 participants (IQR 21 to 150). Overall, 64% of trials (n=698) were prospectively registered, 46% (n=500) had summary results reported in the registry, 69% (n=750) had results published as articles, and an additional 3% (n=36) as abstracts or posters. Results reporting (summary, articles, abstracts or posters) occurred for 58% of trials (n=637) within 2 years, and for 81% (n=888) within 5 years of study primary completion date. Of journal publications, 77% (n=579) were open access publications, 37% (n=276) had trial registration numbers listed in their abstract, and 45% (n=336) in the manuscript. Only 92 (8%) of these trials were legally required to report results, and only 2 (2%) of those were overdue and under primary responsibility of a California university to report. Conclusions Almost one fifth of clinical trials with primary completion dates from 2014 to 2017 with investigators, sponsors or responsible parties affiliated with seven California biomedical research universities lacked any results reporting 5 years after their primary completion, and only 58% reported results within 2 years. Even though a large majority of these trials were completed before US legal mandates for reporting, there was an ethical requirement that the burden to research participants should be commensurate with the scientific value of the research. Research has no public scientific value if its results are not reported.


  • Open Access

    Results reporting for clinical trials led by medical universities and university hospitals in the nordic countries was often missing or delayed

    by Gustav Nilsonne, Susanne Wieschowski, Nicholas J. DeVito, Maia Salholz-Hillel, Love Ahnström, Till Bruckner, Katarzyna Klas, Tarik Suljic, Samruddhi Yerunkar, Natasha Olsson, et al.


  • Open Access

    Measurement challenges and causes of incomplete results reporting of biomedical animal studies: Results from an interview study

    by Till Bruckner, Susanne Wieschowski, Miriam Heider, Susanne Deutsch, Natascha Drude, Ulf Tölch, André Bleich, René Tolba, Daniel Strech

    Background: Existing evidence indicates that a significant amount of biomedical research involving animals remains unpublished. At the same time, we lack standards for measuring the extent of results reporting in animal research. Publication rates may vary significantly depending on the level of measurement such as an entire animal study, individual experiments within a study, or the number of animals used. Methods: Drawing on semi-structured interviews with 18 experts and qualitative content analysis, we investigated challenges and opportunities for the measurement of incomplete reporting of biomedical animal research with specific reference to the German situation. We further investigate causes of incomplete reporting. Results: The in-depth expert interviews revealed several reasons for why incomplete reporting in animal research is difficult to measure at all levels under the current circumstances. While precise quantification based on regulatory approval documentation is feasible at the level of entire studies, measuring incomplete reporting at the more individual experiment and animal levels presents formidable challenges. Expert-interviews further identified six drivers of incomplete reporting of results in animal research. Four of these are well documented in other fields of research: a lack of incentives to report non-positive results, pressures to ‘deliver’ positive results, perceptions that some data do not add value, and commercial pressures. The fifth driver, reputational concerns, appears to be far more salient in animal research than in human clinical trials. The final driver, socio-political pressures, may be unique to the field. Discussion: Stakeholders in animal research should collaborate to develop a clear conceptualisation of complete reporting in animal research, facilitate valid measurements of the phenomenon, and develop incentives and rewards to overcome the causes for incomplete reporting.


  • Open Access

    Results dissemination from completed clinical trials conducted at German university medical centers remained delayed and incomplete. The 2014 –2017 cohort

    by Nico Riedel, Susanne Wieschowski, Till Bruckner, Martin R. Holst, Hannes Kahrass, Edris Nury, Joerg J. Meerpohl, Maia Salholz-Hillel, Daniel Strech


  • Open Access

    Results dissemination from completed clinical trials conducted at German university medical centers remains delayed and incomplete. The 2014-2017 cohort

    by Nico Riedel, Susanne Wieschowski, Till Bruckner, Martin R. Holst, Hannes Kahrass, Edris Nury, Joerg J. Meerpohl, Maia Salholz-Hillel, Daniel Strech

    Objective Timely publication of clinical trial results is central for evidence-based medicine. The performance of university medical centers (UMCs) regarding timely results publication informs the local and national decision makers, patients, and the public about the need to improve trial results dissemination. Study Design and Setting Following the same search and tracking methods used in our previous study for the years 2009 - 2013, we identified trials led by German UMCs completed between 2014 and 2017 and tracked results dissemination for the identified trials. Results We identified 1,658 trials in the 2014-2017 cohort. Of these trials, 43% published results as either journal publication or summary results within 24 months after completion date, which is an improvement of 3.8% percentage points compared to the previous study. At the UMC level, the 24-month publication rates varied from 14% to 71%. Five years after completion, still 30% of the trials remained unpublished. Conclusion Despite minor improvements compared to the previously investigated cohort, the rate of timely reporting of trials led by German UMCs remains low. German UMCs should take further steps to improve timely reporting rates.


  • Open Access

    Dataset for the IntoValue 1 + 2 studies on results dissemination from clinical trials conducted at German university medical centers completed between 2009 and 2017

    by Nico Riedel, Susanne Wieschowski, Till Bruckner, Martin R. Holst, Hannes Kahrass, Edris Nury, Joerg J. Meerpohl, Maia Salholz-Hillel, Daniel Strech


  • Open Access

    Dataset for the IntoValue 1 + 2 studies on results dissemination from clinical trials conducted at German university medical centers completed between 2009 and 2017

    by Nico Riedel, Susanne Wieschowski, Till Bruckner, Martin R. Holst, Hannes Kahrass, Edris Nury, Joerg J. Meerpohl, Maia Salholz-Hillel, Daniel Strech


  • Open Access

    Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies

    by Soeren Sievers, Susanne Wieschowski, Daniel Strech

    Aim: Meaningful and ethical phase I/II trials can only be conducted with supportive prospective risk‐benefit assessment. This relies largely on preclinical animal studies addressing the safety and efficacy of treatments. These studies are reported in an Investigator's Brochure (IB) to inform ethics review boards and regulatory authorities. Our study investigated the extent, reporting quality and accessibility of preclinical safety studies (PCSSs) compiled in IBs.Methods: We analysed a sample of 46 IBs for phase I/II trials approved at a leading German university medical centre from 2010 to 2016. We extracted all PCSSs presented in the 46 IBs and assessed them for reporting on methodological measures to reduce validity threats.Results: The 46 IBs included 777 PCSSs. Blinded outcome assessment, randomization and sample size calculation were reported for fewer than 1% of studies. Only 5% of the PCSSs provided a reference to published data. Compliance with Good Laboratory Practice (GLP) guidance was reported for 52% of PCSSs, but the GLP document itself does not include any relevant methodological requirements for the reduction of validity threats.Conclusion: Scarce reporting in IBs and the very limited publicly available data on PCSSs make it almost impossible for investigators to critically evaluate the robustness of preclinical evidence of drug safety. Combined with recent findings on the presentation of preclinical efficacy studies in IBs, we conclude that the current reporting patterns in IBs strongly limit the independent review of evidential support for early human trials. Regulatory authorities and IRBs should require better reporting in IBs.


  • Open Access

    Results dissemination of registered clinical trials across Polish academic institutions: a cross-sectional analysis

    by Karolina Strzebonska, Mateusz T Wasylewski, Lucja Zaborowska, Nico Riedel, Susanne Wieschowski, Daniel Strech, Marcin Waligora

    Objectives To establish the rates of publication and reporting of results for interventional clinical trials across Polish academic medical centres (AMCs) completed between 2009 and 2013. We aim also to compare the publication and reporting success between adult and paediatric trials. Design Cross-sectional study. Setting AMCs in Poland. Participants AMCs with interventional trials registered on ClinicalTrials.gov. Main outcome measure Results reporting on ClinicalTrials.gov and publishing via journal publication. Results We identified 305 interventional clinical trials registered on ClinicalTrials.gov, completed between 2009 and 2013 and affiliated with at least one AMC. Overall, 243 of the 305 trials (79.7%) had been published as articles or posted their summary results on ClinicalTrials.gov. Results were posted within a year of study completion and/or published within 2 years of study completion for 131 trials (43.0%). Dissemination by both posting and publishing results in a timely manner was achieved by four trials (1.3%). Conclusions Our cross-sectional analysis revealed that Polish AMCs fail to meet the expectation for timely disseminating the findings of all interventional clinical trials. Delayed dissemination and non-dissemination of trial results negatively affects decisions in healthcare.